Ravindra Prasad Thokala: When T Cells Heal and Harm in the Same Transplant Unit
Ravindra Prasad Thokala, Transfusion Medicine Consultant and Head at Apollo Cancer Center, shared a post on LinkedIn:
“Two patients, two cell therapies, two opposite ends of the same immune system — and a striking reminder of why this cellular therapy is equal parts thrilling and humbling.
The first: adenovirus-specific T cells (CD4 and CD8) at a 5 million cell dose, prepared against refractory adenoviremia after a stem cell transplant, when the patient’s own reconstituting immunity and neither the list of antivirals simply cannot control the virus.
With turnaround — under 36 hours from leukapheresis to infusion (helped by Cytocare technologies for such a processing in the shortest time) — because in this race that speed can be the difference between staying ahead of the virus and forever chasing it.
The second: extracorporeal photopheresis for aggressive (fiery) acute skin GvHD, where the problem is the exact opposite — donor T cells that have turned on the patient’s own tissue, leaving the skin you see here.
Rather than simply suppressing those cells, photopheresis collects, treats and returns them in a way that tames the T cells gone rogue , same time gently retrains the immune response.
One therapy adds T cells to deliver might Against a virus; the other tames T cells that target the host — same cells, opposite missions, one shared goal of carrying a transplant patient safely through.
This is the reality of cellular therapy:
You would never wish either situation on a patient, but working in this space … you will eventually meet both.
Grateful to a team that can pivot between building immunity and calming it, sometimes on the very same day — and now we wait, watch and hope for both responses.”
Stay updated with Hemostasis Today.
-
Sep 21, 2026, 20:56George Touma: ApoB Should Be Central to All Lipid Guidlines
-
Sep 21, 2026, 20:55Christopher Robinson: Obstetric Risks Are Seen at the Extremes of Birthweight
-
Sep 21, 2026, 20:54Emicizumab for Refractory GI Bleeding in Myeloma-Associated Acquired VWD – JTH
-
Sep 21, 2026, 20:52Ross Baker: ASH 2026 Guidelines on Iron Deficiency in HMB and Bleeding Disorders
-
Sep 21, 2026, 20:50Rainer Kaiser: Genes and Signalling Pathways Implicated in Procoagulant Platelet Generation
-
Sep 21, 2026, 20:49Natalia Dovlatova: Celebrating Stan Heptinstall and His Legacy in Platelet Science
-
Sep 21, 2026, 20:48Norm Roulet: The Interaction of Pb and SARS-CoV-2 and Its Impact on the Cardiovascular System
-
Sep 21, 2026, 20:45Felix Scholkmann: The Spleen Plays a Key Role in Regulating Platelet Activity
-
Sep 21, 2026, 20:43Claire Pomeroy: Celebrating the 2026 Lasker Awards and Why Medical Research Matters